Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens. We show 24 historical shares outstanding datapoints in our RCUS shares outstanding history coverage, used to compute RCUS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RCUS market cap history over the course of time is important for investors
interested in comparing RCUS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RCUS versus a peer is one thing; comparing
RCUS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RCUS can fluctuate over the course of history.
With this page we aim to empower investors researching RCUS by allowing them to research the RCUS market cap history. |
Free RCUS Email Alerts:
Video: The Importance of Market Cap
